HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry

Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · May 21, 2024

Keywords

ClinConnect Summary

The HF2 Registry, or Hemodynamic Frontiers in Heart Failure Registry, is a study designed to gather important information about patients with heart failure who have received a special device called a pulmonary artery pressure sensor. This device helps monitor heart function and can guide treatment decisions. By collecting details about patients' health and experiences, the researchers aim to improve understanding of heart failure management and develop better therapies for those living with this condition.

To participate in the trial, individuals must be between the ages of 65 and 100 years and have heart failure that has required hospitalization in the past. They may also qualify if they have elevated levels of a substance called BNP without needing to be hospitalized or if they have mild heart failure symptoms. Participants can expect to share their health information as part of a larger effort to enhance heart failure care. It's important to note that individuals under 18, pregnant women, or those unable to keep regular follow-up appointments at a heart failure clinic cannot join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All patients would have been or will be implanted per indications from FDA approval/CHAMPION trial. These would be patients with NYHA (New York Heart Association) Class III heart failure who had a prior hospitalization.
• • 2. Patients who meet the expanded FDA indication (BNP elevation without hospitalization or NYHA class II).
• Exclusion Criteria:
• • 1. Patients less than 18 years of age.
• • 2. Pregnant women at the scheduled time of PA pressure sensor implant.
• • 3. Patients unable or unwilling to have continuity of care in the heart failure clinic.

Trial Officials